Literature DB >> 24633744

Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: is there a right or wrong way?

Farhad Ravandi1.   

Abstract

Although combination chemotherapy regimens have been clearly successful in treating a proportion of patients with acute leukemia, we are probably close to a ceiling of maximal benefit from such combinations. Identification of targets in the cellular signaling pathways and development of specific drugs against them have added to our armamentarium; our current challenge is how to best incorporate these agents into the currently available regimens.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24633744     DOI： 10.1007/s11899-014-0204-7

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  30 in total

1.  Evaluation of a new chemotherapeutic agent in patients with 'advanced refractory' acute leukemia. Studies of 6-azauracil.

Authors:  E J FREIREICH; E FREI; J F HOLLAND; D PINKEL; O SELAWRY; H ROTHBERG; F HAURANI; R TAYLOR; E A GEHAN
Journal:  Blood       Date:  1960-09       Impact factor: 22.113

2.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

3.  National Cancer Act of 1971--an editorial.

Authors:  S Weinhouse
Journal:  Cancer Res       Date:  1972-04       Impact factor: 12.701

4.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

5.  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.

Authors:  S L Soignet; S R Frankel; D Douer; M S Tallman; H Kantarjian; E Calleja; R M Stone; M Kalaycio; D A Scheinberg; P Steinherz; E L Sievers; S Coutré; S Dahlberg; R Ellison; R P Warrell
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

6.  Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Authors:  Jorge E Cortes; Hagop Kantarjian; James M Foran; Darejan Ghirdaladze; Mamia Zodelava; Gautam Borthakur; Guy Gammon; Denise Trone; Robert C Armstrong; Joyce James; Mark Levis
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

7.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

8.  Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Authors:  Farhad Ravandi; Mona Lisa Alattar; Michael R Grunwald; Michelle A Rudek; Trivikram Rajkhowa; Mary Ann Richie; Sherry Pierce; Naval Daver; Guillermo Garcia-Manero; Stefan Faderl; Aziz Nazha; Marina Konopleva; Gautam Borthakur; Jan Burger; Tapan Kadia; Sara Dellasala; Michael Andreeff; Jorge Cortes; Hagop Kantarjian; Mark Levis
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

9.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

Authors:  Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

10.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245
View more
  1 in total

1.  Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells.

Authors:  Yoshihiro Umezawa; Tetsuya Kurosu; Hiroki Akiyama; Nang Wu; Ayako Nogami; Toshikage Nagao; Osamu Miura
Journal:  Oncotarget       Date:  2016-07-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.